Evidence map›Paper›PMID 16278527›Full record

ReviewJournal of clinical hypertension (Greenwich, Conn.)2005

Pharmacotherapy review: Angiotensin receptor antagonists.

Domenic A Sica

Abstract readReview
In one paragraph

Review in Journal of clinical hypertension (Greenwich, Conn.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Angiotensin receptor blockers: new considerations in their mechanism of action.Journal of clinical hypertension (Greenwich, Conn.) · 2006
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Domenic A SicaSection of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298-0160, USA. dsica@hsc.vcu.edu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiotensin receptor blockers are one of several drug classes that act by interfering with activity of the renin-angiotensin axis. Drugs in this class are as effective as angiotensin-converting enzyme inhibitors in the reduction of blood pressure in hypertensive patients. Results from a series of outcomes trials increasingly support the use of drugs in this class as cardioprotective and renoprotective agents in patients with heart failure, diabetic nephropathy, and post-myocardial infarction.

Indexed as

Angiotensin II Type 1 Receptor BlockersDrug Therapy, CombinationHumansHypertensionRenin-Angiotensin SystemUnited StatesAngiotensin II Type 1 Receptor Blockers

Identifiers

PMID16278527
PMCPMC8109488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.